Nektar Therapeutics (NKTR)

5.14 +0.19 (+3.84%) USD  |  NASDAQ  |  Aug 12, 16:00
5.14 0.00 (0.00%) After-Hours: 20:00
More

Nektar Therapeutics News

News

Headline
Wire
Time (ET)
--JPMorgan Downgrades Nektar Therapeutics to Underweight From Neutral
MT Newswires
08/08 05:25
Nektar's (NKTR) Q2 Earnings and Revenues Miss Estimates
Yahoo
08/05 12:11
Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates
Yahoo
08/04 18:15
-- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q2 Revenue $21.6M
MT Newswires
08/04 16:30
Nektar Therapeutics Reports Second Quarter 2022 Financial Results
PR Newswire
08/04 16:15
Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets
PR Newswire
07/26 18:00
Catalyst (CPRX) Stock Jumps 10%: Will It Continue to Soar?
Yahoo
07/14 06:01
Nektar Therapeutics Promotes Jillian Thomsen to CFO
MT Newswires
07/01 06:54
Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer
PR Newswire
07/01 06:30
Jefferies & Co. Assumes Nektar Therapeutics at Hold, Adjust Price Target to $4 From $12
MT Newswires
05/31 11:12
After a record-breaking decade, biotech is discovering what hard times feel like
Yahoo
05/27 08:00
Research Alert: CFRA Maintains Hold Opinion On Shares Of Nektar Therapeutics
MT Newswires
05/25 10:15
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
Yahoo
05/16 14:09
-- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q1 Revenue $24.8M
MT Newswires
05/05 16:44
Nektar Therapeutics Reports First Quarter 2022 Financial Results
PR Newswire
05/05 16:15
Nektar Therapeutics Plans to Focus Resources on Key Research; Cuts 70% of Workforce; Extends Cash Runway to H1 2025
MT Newswires
04/25 17:12
Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook
PR Newswire
04/25 16:30
Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
PR Newswire
04/23 17:30
Oppenheimer Adjusts Nektar Therapeutics Price Target to $5 From $6, Maintains Perform Rating
MT Newswires
04/20 10:56
Correction: Sector Update: Health Care Stocks Stumble Monday Afternoon
MT Newswires
04/19 11:27
Hot Stocks: CASA soars on VZ investment; SWX potential bidding war; TGTX, NKTR drop on drug setbacks
SA Breaking News
04/18 18:46
Sector Update: Health Care Stocks Stumble Monday Afternoon
MT Newswires
04/18 16:00
Sector Update: Health Care Stocks Retreating to Begin New Week
MT Newswires
04/18 14:21
Update: Nektar Therapeutics Plunges After Joint Trials With Bristol-Myers Squibb Stopped for Cancer Combination Therapy
MT Newswires
04/18 14:01
Top Midday Decliners
MT Newswires
04/18 13:43
VIRX, ARQQ and GWGH among mid-day movers
SA Breaking News
04/18 12:37
Goldman Sachs Downgrades Nektar Therapeutics to Sell from Neutral, Sets $3 Price Target
MT Newswires
04/18 11:10
Thinking about buying stock in DiDi Global, Borqs Technologies, Aterian, Nektar Therapeutics, or TG Therapeutics?
PR Newswire
04/18 11:01
Nektar stock slumps 36% on Goldman Sachs downgrade following bempeg program termination
SA Breaking News
04/18 10:25
SVB Leerink Adjusts Nektar Therapeutics' Price Target to $6 from $7, Keeps Market Perform Rating
MT Newswires
04/18 10:13
Sector Update: Health Care Stocks Modestly Lower Pre-Bell Monday
MT Newswires
04/18 09:20
Wall Street Set for Narrow Losses Amid Rising Bond Yields
MT Newswires
04/18 09:14
Top Premarket Decliners
MT Newswires
04/18 08:02
Mizuho Securities Adjusts Price Target on Nektar Therapeutics to $6 From $8, Maintains Neutral Rating
MT Newswires
04/18 07:38
Nektar Therapeutics, Bristol-Myers Squibb Stop Trials of Cancer Combination Therapy
MT Newswires
04/18 04:30
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
PR Newswire
04/14 16:30
Goldman screens companies with best and worst pricing power into earnings season
SA Breaking News
04/11 07:48
HYZN, CGEN and MRIN among after hour movers
SA Breaking News
03/28 17:59
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
PR Newswire
03/26 00:37
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
PR Newswire
03/16 20:31
Canaccord Genuity Adjusts Nektar Therapeutics' Price Target to $6 From $25, Reiterates Buy Rating
MT Newswires
03/16 09:56
SVB Leerink Adjusts Nektar Therapeutics' Price Target to $7 from $18, Keeps Market Perform Rating
MT Newswires
03/15 10:02
Mizuho Securities Downgrades Nektar Therapeutics to Neutral From Buy, Adjusts Price Target to $8 From $35
MT Newswires
03/15 06:05
Cowen Downgrades Nektar Therapeutics to Market Perform From Outperform
MT Newswires
03/15 02:14
Hot Stocks: Fintechs fall; Berkshire Hathaway tests $500K; GME hits low; NKTR plunges; TRQ rallies
SA Breaking News
03/14 18:18
Sector Update: Health Care Advancing to Begin New Week
MT Newswires
03/14 15:50
Research Alert: CFRA Keeps Hold Opinion On Shares Of Nektar Therapeutics
MT Newswires
03/14 13:40
Sector Update: Health Care Stocks Helping Limit Broader Market Declines
MT Newswires
03/14 13:33
Top Midday Decliners
MT Newswires
03/14 13:29
KC, DADA and ARQQ among mid-day movers
SA Breaking News
03/14 12:53
--Oppenheimer Downgrades Nektar Therapeutics to Market Perform From Outperform, Adjusts Price Target to $6 From $21
MT Newswires
03/14 12:13
BTIG Research Downgrades Nektar Therapeutics to Neutral From Buy
MT Newswires
03/14 12:12
--William Blair Downgrades Nektar Therapeutics to Market Perform Form Outperform, Adjusts Price Target to $4.49 From $10.98
MT Newswires
03/14 12:12
BofA Securities Downgrades Nektar Therapeutics to Underperform from Neutral, Adjusts Price Target to $6 from $18
MT Newswires
03/14 11:39
Zhongchao, Moderna top healthcare gainers; Nektar, MultiPlan lead losers' pack
SA Breaking News
03/14 10:06
Wall Street Set for Narrow Gains, Russia-Ukraine Talks in Focus
MT Newswires
03/14 09:15
Top Premarket Decliners
MT Newswires
03/14 08:06
Bristol-Myers, Nektar Therapeutics Study of Melanoma Treatment Fails to Meet Endpoints; Nektar Shares Tumble
MT Newswires
03/14 07:47
Oppenheimer Upgrades Nektar Therapeutics to Outperform From Perform, Maintains $21 Price Target
MT Newswires
03/09 09:26
Research Alert: CFRA Keeps Hold Opinion On Shares Of Nektar Therapeutics
MT Newswires
03/01 16:55
Nektar Therapeutics Reports Narrower-Than-Expected Q4 Loss
MT Newswires
02/28 16:31
-- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q4 Revenue $25M, vs. Street Est of $25.3M
MT Newswires
02/28 16:23
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
PR Newswire
02/28 16:15
Earnings Reaction History: Nektar Therapeutics, 33.3% Follow-Through Indicator, 7.3% Sensitive
MT Newswires
02/28 12:10
Notable earnings after Monday's close
SA Breaking News
02/27 17:35
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
PR Newswire
01/05 09:00
Thinking about buying stock in Naked Brand, Pioneer Power Solutions, Rite Aid, Nektar Therapeutics, or Can Fite Biopharma?
PR Newswire
12/21 11:18
Nektar Therapeutics reports phase 1b data for NKTR-358 study in atopic dermatitis
SA Breaking News
12/15 09:47
Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis
PR Newswire
12/15 09:10
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting
PR Newswire
12/13 09:00
Signature Bank, SolarEdge Technologies and FactSet Research Systems Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
PR Newswire
12/03 19:52
Signature Bank, SolarEdge, FactSet head into S&P 500
SA Breaking News
12/03 17:30
Nektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting
PR Newswire
11/30 08:00
Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D.
PR Newswire
11/15 08:30
Research Alert: CFRA Maintains Hold Opinion On Shares Of Nektar Therapeutics
MT Newswires
11/08 17:55
--Benchmark Upgrades Nektar Therapeutics to Buy From Hold; Price Target is $20
MT Newswires
11/08 07:50
Nektar Therapeutics Q3 Loss Widens as Revenue Drops; Shares Slump 21%
MT Newswires
11/05 11:30
--Oppenheimer Adjusts Nektar Therapeutics PT to $21 From $25, Maintains Perform Rating
MT Newswires
11/05 10:46
-- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q3 Revenue $24.9M, vs. Street Est of $27.9M
MT Newswires
11/04 16:15
Nektar Therapeutics Reports Third Quarter 2021 Financial Results
PR Newswire
11/04 16:15
Redhill Biopharma, AstraZeneca, Nektar Therapeutics Settle Movantik Patent Litigation with Aurobindo
MT Newswires
09/23 10:05
Thinking about trading options or stock in Ambarella, Robinhood Markets, Lucid Group, Adobe, or Nektar Therapeutics?
PR Newswire
09/22 09:31
Nektar Therapeutics Partners With Pfizer, Merck for Clinical Trial
MT Newswires
09/21 10:52
Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study
PR Newswire
09/21 09:00
Research Alert: CFRA Reiterates Hold Opinion On Shares Of Nektar Therapeutics
MT Newswires
08/06 15:45
Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets
PR Newswire
07/27 18:00
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
PR Newswire
07/19 09:00
Exelixis inks collaboration and supply agreement with Bristol Myers Squibb for cancer study
SA Breaking News
06/14 08:33
Exelixis Working With Bristol-Myers to Launch Early-Stage Study of Potential Tumor Drug XL092
MT Newswires
06/14 08:28
Ra Medical Systems, Liminal BioSciences leads healthcare gainers; Cabaletta Bio, MacroGenics among major new losers
SA Breaking News
06/07 11:02
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference
PR Newswire
06/07 08:30
Nektar Therapeutics Publishes Pre-Clinical Data of NKTR-358 for Autoimmune, Inflammatory Disorders
MT Newswires
05/20 12:08
Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity
PR Newswire
05/20 11:00
Nektar Therapeutics' NKTR-255 shows encouraging action in anti-tumor activity
SA Breaking News
05/18 09:59
Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)
PR Newswire
05/18 08:00
Nektar Therapeutics shares rise on narrower Q1 loss
SA Breaking News
05/07 11:43
Research Alert: CFRA Maintains Hold Opinion On Nektar Therapeutics
MT Newswires
05/07 10:05
-- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q1 Revenue $23.6M, vs. Street Est of $25.7M
MT Newswires
05/06 16:15
Nektar Therapeutics Reports First Quarter 2021 Financial Results
PR Newswire
05/06 16:15
Earnings Reaction History: Nektar Therapeutics, 33.3% Follow-Through Indicator, 6.1% Sensitive
MT Newswires
05/06 12:31
Nektar to Announce Financial Results for the First Quarter 2021 on Thursday, May 6, 2021, After Close of U.S.-Based Financial Markets
PR Newswire
04/27 18:00
Sanofi confirms partial response for cancer therapy in mid-stage study
SA Breaking News
04/09 13:25
Analyst Actions: SVB Leerink Adjusts Price Target on Nektar Therapeutics to $21 From $20, Maintains Market Perform Rating
MT Newswires
04/06 10:35
Redhill Reaches Settlement With MSN Pharmaceuticals Over Movantik Patent Litigation
MT Newswires
03/25 10:39
Research Alert: CFRA Keeps Hold Opinion On Nektar Therapeutics
MT Newswires
03/05 12:30
Research Alert: CFRA Keeps Hold Opinion On Nektar Therapeutics
MT Newswires
02/26 12:25
Nektar Therapeutics Q4 EPS Loss a Penny Wider on Lower Revenue
MT Newswires
02/25 17:41
-- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q4 Revenue $23.5M, vs. Street Est of $29.9M
MT Newswires
02/25 16:18
Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results
PR Newswire
02/25 16:15
Notable earnings after Thursday's close
SA Breaking News
02/24 17:35
--Analyst Actions: Benchmark Capital Downgrades Nektar Therapeutics to Hold From Buy
MT Newswires
02/22 08:42
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets
PR Newswire
02/18 17:30
Thinking about trading options or stock in Nektar Therapeutics, Sleep Number, General Electric, Twilio, or Spirit Airlines?
PR Newswire
02/18 09:31
Stocks End Mixed After Strong Retail Sales Report; Verizon, Chevron Lift Dow to Record High
MT Newswires
02/17 17:23
Close Update: Stocks End Mixed After Strong Retail Sales Report; Verizon, Chevron Lift Dow to Record High
MT Newswires
02/17 16:34
Sector Update: Health Care Stocks Firming Just Ahead of Wednesday Close
MT Newswires
02/17 15:58
Sector Update: Health Care Stocks Nudging Higher on Wednesday
MT Newswires
02/17 14:01
Midday Report: Wall Street Slips Midday Amid Retail Sales Jump, Rising Treasury Yields
MT Newswires
02/17 12:51
Nektar and Merck team up in mid-stage cancer combo study
SA Breaking News
02/17 10:59
Nektar to Collaborate with SFJ for Development of Bempegaldesleukin in Head and Neck Cancer -- Shares Jump
MT Newswires
02/17 10:21
Thinking about trading options or stock in Vir Biotechnology, Verizon, Nektar Therapeutics, Chevron, or Estee Lauder?
PR Newswire
02/17 09:31
Nektar to Collaborate with Merck on Phase 2/3 Study of a Potential Carcinoma Combination Treatment
MT Newswires
02/17 09:26
Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
PR Newswire
02/17 08:00
Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer
PR Newswire
02/17 07:59
Thinking about trading options or stock in Nektar Therapeutics, Pfizer, AstraZeneca, Vir Biotechnology, or Esperion Therapeutics?
PR Newswire
02/01 09:31
Should you invest in Dillard's, Inovio Pharmaceuticals, Eli Lilly, Nektar Therapeutics, or Carnival Corp?
PR Newswire
01/29 11:15
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
PR Newswire
01/06 17:00
Analyst Actions: Stifel Starts Nektar Therapeutics at Hold With $18 Price Target
MT Newswires
01/06 08:05
Nektar Therapeutics Names Interim Chief Medical Officer
MT Newswires
01/05 16:40
Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development
PR Newswire
01/05 16:20
Nektar Therapeutics to Sell Royalties for Adynovate and Movantik to Healthcare Royalty $150 Million
MT Newswires
12/22 09:38
Nektar to sell Adynovate, Movantik Royalties for $150M
SA Breaking News
12/22 09:04
Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million
PR Newswire
12/22 08:30
Nektar Therapeutics raised to ‘Hold’ from ‘Sell’ at CFRA on encouraging clinical data
SA Breaking News
12/16 11:56
Research Alert: CFRA Raises Opinion On Nektar Therapeutics To Hold From Sell
MT Newswires
12/16 01:25
Nektar Therapeutics Doses First Patient in Study of Cancer Drug Candidate
MT Newswires
12/15 09:13
Dosing underway in Nektar Therapeutics' study of NKTR-255+cetuximab in head, neck and colorectal cancer
SA Breaking News
12/15 09:04
Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer
PR Newswire
12/15 08:30
SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of EQT, ZYNE, NKTR, and FMO; Shareholders are Encouraged to Contact the Firm
Globe Newswire
12/08 06:00
Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting
PR Newswire
12/07 16:00
Research Alert: CFRA Maintains Sell Opinion On Nektar Therapeutics
MT Newswires
12/04 12:10
Analyst Actions: SVB Leerink Adjusts Nektar Therapeutics' Price Target to $20 from $17, Keeps Market Perform Rating
MT Newswires
11/12 12:07
Nektar Therapeutics immuno-oncology candidates show positive action in early-stage studies
SA Breaking News
11/11 15:52
Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PR Newswire
11/11 14:00
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
PR Newswire
11/09 08:00
Sector Update: Late Slide Trims Friday Rise for Health Care Stocks
MT Newswires
11/06 16:05
Research Alert: CFRA Keeps Sell Opinion On Nektar Therapeutics
MT Newswires
11/06 15:35
Nektar Therapeutics Reports Q3 Loss of $0.61 a Share, Beating Estimates
MT Newswires
11/05 17:14
-- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q3 EPS $-0.61, vs. Street Est of $-0.75
MT Newswires
11/05 16:27
-- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q3 Revenue $30M, vs. Street Est of $22.8M
MT Newswires
11/05 16:27
Nektar Therapeutics Reports Third Quarter 2020 Financial Results
PR Newswire
11/05 16:15
Notable earnings after Thursday's close
SA Breaking News
11/04 17:35
Nektar Therapeutics Releases Data on Lupus Drug Candidate Study Showing Reduction in Disease Activity
MT Newswires
11/04 11:44
New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress
PR Newswire
11/04 10:15
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress
PR Newswire
10/29 18:00
Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets
PR Newswire
10/28 18:00
Nektar Therapeutics Says FDA Cleared Drug Application for COVID-19 Drug Candidate; to Launch Phase 1b Study
MT Newswires
10/27 11:20
Nektar Therapeutics on go with study of bempegaldesleukin in COVID-19
SA Breaking News
10/27 07:54
Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19
PR Newswire
10/27 07:30
Analyst Actions: JPMorgan Starts Nektar Therapeutics at Neutral With $26 Price Target
MT Newswires
09/14 08:59
--Analyst Actions: SVB Leerink Cuts Nektar Therapeutics' Price Target to $17 From $18, Keeps at Market Perform
MT Newswires
08/14 09:49
Nektar Therapeutics, Vaccibody Dose First Patient in Study Evaluating Their Combination Drug for Cancer
MT Newswires
08/12 08:58
Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck
PR Newswire
08/12 08:00
Research Alert: CFRA Retains Sell Opinion On Nektar Therapeutics
MT Newswires
08/07 15:10
-- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q2 EPS $-0.45, vs. Street Est of $-0.69
MT Newswires
08/06 16:23
-- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q2 Revenue $48.847M, vs. Street Est of $22.8M
MT Newswires
08/06 16:22
Nektar Therapeutics Reports Second Quarter 2020 Financial Results
PR Newswire
08/06 16:15
Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets
PR Newswire
07/28 18:00
Research Alert: CFRA Cuts View On Shares Of Nektar Therapeutics To Sell From Hold
MT Newswires
06/10 09:25
Nektar Therapeutics Says Study Shows Potential of Autoimmune Disease Drug Candidate
MT Newswires
06/05 05:45
Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
PR Newswire
06/04 17:00
Nektar Therapeutics to host webcast on NKTR-358 data June 5
SA Breaking News
05/30 12:56
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
PR Newswire
05/29 17:00
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal
PR Newswire
05/22 08:30
--Analyst Actions: Oppenheimer Lifts Nektar Therapeutics PT to $25 From $24, Maintains Perform Rating
MT Newswires
05/18 10:10
Research Alert: CFRA Keeps Hold Opinion On Nektar Therapeutics
MT Newswires
05/08 17:15
Nektar Therapeutics Reports First Quarter 2020 Financial Results
PR Newswire
05/07 16:15
Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets
PR Newswire
04/28 17:00
--Analyst Actions: Benchmark Capital Initiates Coverage on Nektar Therapeutics With Buy Rating, $26 Price Target
MT Newswires
04/22 10:12
BofA likes Johnson & Johnson in premarket analyst action
SA Breaking News
04/22 07:38
RemeGen candidate Fast Track'd for lupus
SA Breaking News
04/15 11:13
Incyte details late-stage data on ruxolitinib cream for atopic dermatitis
SA Breaking News
04/05 14:55
Analyst Actions: Goldman Sachs Upgrades Nektar Therapeutics to Neutral From Sell, Lifts Price Target to $20 From $18
MT Newswires
03/30 08:57
Raymond James likes Amgen in premarket analyst action
SA Breaking News
03/30 08:06
--Analyst Actions: JPMorgan Cuts Price Target on Nektar Therapeutics to $27 From $28, Maintains Neutral
MT Newswires
03/09 10:06
--Analyst Actions: Barclays Initiates Coverage on Nektar Therapeutics With Overweight Rating, $30 Price Target
MT Newswires
03/04 08:11
Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference
PR Newswire
02/28 18:30
Research Alert: CFRA Keeps Hold Opinion On Nektar Therapeutics
MT Newswires
02/28 11:10
MT Newswires After-Hours News Movers
MT Newswires
02/27 17:55
Nektar Therapeutics Posts Narrower-Than-Expected Q4 Net Loss; Revenue Beats -- Shares Jump After-Hours
MT Newswires
02/27 16:57
Nektar Therapeutics EPS beats by $0.03, beats on revenue
SA Breaking News
02/27 16:17
Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results
PR Newswire
02/27 16:15
Notable earnings after Thursday's close
SA Breaking News
02/26 17:35
Redhill to Acquire Global Rights to Movantik from AstraZeneca, Secures $115 Million Financing
MT Newswires
02/25 07:53
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets
PR Newswire
02/18 17:00
Data on Nektar Therapeutics' Bempeg Published in Nature Communications; Shares Up 8%
MT Newswires
02/03 14:14
Analyst Actions: Mizuho Securities Upgrades Nektar Therapeutics to Buy From Neutral, Lifts Price Target to $35 From $21
MT Newswires
02/03 08:35
Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications
PR Newswire
02/03 08:00
Mizuho thinks this beat-up biotech has 75% upside
SA Breaking News
02/03 07:59
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics  - NKTR
Globe Newswire
01/29 15:46
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
PR Newswire
01/24 19:02
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Globe Newswire
01/21 17:53
--Analyst Actions: Oppenheimer Lifts PT on Nektar Therapeutics to $24 From $20 on Expanded Melanoma Indication, Keeps Perform Rating
MT Newswires
01/21 09:34
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Globe Newswire
01/16 13:37
Research Alert: CFRA Maintains Hold Opinion On Nektar Therapeutics
MT Newswires
01/16 12:45
After Hours Watch List Scorecard: FLNT, CETX, NKTR
MT Newswires
01/15 17:11
Close Update: Market Indexes Hit New Intraday Highs; US, China Sign Initial Trade Deal; Dow Surpasses 29,000-Mark on Close
MT Newswires
01/15 16:45
Sector Update: Health Care Stocks Resist Afternoon Slump
MT Newswires
01/15 15:50
Sector Update: Health Care Stocks Advancing in Defensive Trading
MT Newswires
01/15 13:22
HEXO, NKTR, OGI and ACOR among midday movers
SA Breaking News
01/15 12:41
Midday Update: Stocks Climb Ahead of Trump Signing Interim Trade Deal With China
MT Newswires
01/15 12:32
Healthcare - Top 5 Gainers / Losers
SA Breaking News
01/15 11:01
Sector Update: Most Health Care Giants Flat Pre-Bel Wednesday
MT Newswires
01/15 09:22
Wall Street Wavers Pre-Bell Before US, China Sign Trade Deal
MT Newswires
01/15 09:14
NKTR, TGT among premarket losers
SA Breaking News
01/15 09:10
Sector Update: Health Care
MT Newswires
01/15 08:53
MT Newswires Opening Bell Momentum Stocks: NKTR
MT Newswires
01/15 08:03
Nektar bails on oxycodegol after negative Ad Com vote
SA Breaking News
01/15 06:44
Nektar Therapeutics Withdraws NDA for Chronic Pain Treatment Oxycodegol; Shares Down 14% Pre-Market
MT Newswires
01/15 05:07
Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
PR Newswire
01/14 22:47
MT Newswires After-Hours Watch List: FLNT, CETX, NKTR
MT Newswires
01/14 17:56
MT Newswires After-Hours News Movers
MT Newswires
01/14 17:50
OGI, NKTR, TCOM and VHC among after hour movers
SA Breaking News
01/14 17:36
FDA Advisers Vote 27-0 Against Nektar Therapeutics' opioid Drug Oxycodegol for Chronic Low Back Pain - Stock Drops 10% After-Hours
MT Newswires
01/14 17:03
FDA advisory groups thumbs down on Nektar's oxycodegol
SA Breaking News
01/14 16:36
Nektar rallies ahead of Ad Com vote on oxycodegol
SA Breaking News
01/14 13:53
Ad Com tomorrow for Nektar's oxycodegol
SA Breaking News
01/13 15:21
Thinking about buying stock in Bilibili, Microsoft, Nio, Nektar Therapeutics, or NVIDIA?
PR Newswire
01/13 09:31
Research Alert: CFRA Maintains Hold Opinion On Nektar Therapeutics
MT Newswires
01/10 15:10
Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued for Misleading Shareholders
Business Wire
01/10 14:32
PTLA, NKTR, SRNE and SIX among midday movers
SA Breaking News
01/10 12:43
Key events next week - healthcare
SA Breaking News
01/10 09:45
Nektar Therapeutics to Advance New Combination Therapies for Cancer in Collaboration With Bristol-Myers
MT Newswires
01/10 09:12
Nektar up 3% premarket on new Bristol-Myers collaboration
SA Breaking News
01/10 08:18
Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)
Business Wire
01/10 06:59
Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
PR Newswire
01/07 09:00
Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.
PR Newswire
12/17 09:00
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
PR Newswire
12/09 10:05
Nektar Therapeutics Hires John Northcott as Chief Commercial Officer
MT Newswires
12/03 09:21
Nektar Appoints John Northcott as Chief Commercial Officer
PR Newswire
12/03 09:00
Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference
PR Newswire
11/13 17:30
--Analyst Actions: Canaccord Genuity Lifts Nektar Therapeutics' Price Target to $24 From $20, Reiterates Buy Rating
MT Newswires
11/12 11:46
Sector Update: Health Care Stocks Ending Near Session Lows
MT Newswires
11/11 15:31
Sector Update: Health Care Weighing on Broader Monday Markets
MT Newswires
11/11 13:39
WBA, SPWR among top premarket gainers
SA Breaking News
11/11 09:25
Sector Update: Health Care Giants Mostly Flat Pre-Market Monday
MT Newswires
11/11 09:07
Nektar up 5% premarket on encouraging NKTR-358 data
SA Breaking News
11/11 08:25
Nektar Therapeutics Reports Results from Separate Studies on Treatments for Melanoma, Autoimmune Diseases
MT Newswires
11/11 03:57
Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
PR Newswire
11/10 11:00
Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PR Newswire
11/09 17:30